Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stallergenes Greer Back On The M&A Beat

Executive Summary

A leading allergy company in Canada has been snapped up by Stallergenes Greer, targeting North America as part of a renewed business development strategy.

You may also be interested in...



Stallergenes Greer's Delisting To Focus Leadership On Facility Issues

The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.

Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO

Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.

Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel